PV Bulletin

CDA-AMC Post-Market Drug Evaluation (PMDE) Program Procedural Update

Canada's Drug Agency updated PMDE program procedures affecting post-market drug safety evaluations and signal assessments.

Primary source: Canada's Drug Agency (CDA-AMC)

PV Impact Brief

MonitoringConfidence: high

What changed

CDA-AMC updated PMDE Program procedures to refine evaluation initiation processes and incorporate real-world data for safety reviews and regulatory decisions.

Why it matters

The update alters how MAHs interact with Canadian authorities during post-market safety evaluations and signal assessments, potentially impacting submission timelines and data requirements.

Action needed

Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Signal ManagementCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Quarterly

Policy change details

Document type
SOP
Policy status
revised
Publication date
2026-06-05
Policy change
Canada's Drug Agency (CDA-AMC) has updated its Post-Market Drug Evaluation (PMDE) Program procedures, which provide national coordination for evaluating drug safety and effectiveness after products enter the market.

Key changes

Refines processes for the initiation of evaluations and the use of real-world data to inform safety reviews and regulatory decisions in Canada.

Affected workflows

Signal ManagementCountry Compliance

Responsible groups

Pharmacovigilance OperationsRegulatory AffairsMedical Affairs

PV impact

Affects the interaction between MAHs and Canadian health authorities during post-market safety evaluations and signal assessments.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.

Canada's Drug Agency (CDA-AMC) updated its Post-Market Drug Evaluation (PMDE) Program, refining processes for initiating evaluations and using real-world data. This affects marketing authorization holders' interaction with Canadian health authorities during post-market safety evaluations and signal assessments.

What changed: CDA-AMC updated PMDE Program procedures to refine evaluation initiation processes and incorporate real-world data for safety reviews and regulatory decisions.

Why it matters: The update alters how MAHs interact with Canadian authorities during post-market safety evaluations and signal assessments, potentially impacting submission timelines and data requirements.

Practical implication: Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Post-Market Safety#Real-World Evidence#Signal Management#SOP#Revised#Canada's Drug Agency (CDA-AMC)#country_requirement#policy-change

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward